



Image

12-08-03

1631
\$

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 937 422 854 US

Date of Deposit: December 4, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Arlington, VA 22313-1450.

April Reeves
April Reeves

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

C. Case *et al.*

Application No.: 09/942,087

Filed: August 28, 2001

For: MODULATION OF ENDOGENOUS
GENE EXPRESSION IN CELLS

Examiner: John S. Brusca

Group Art Unit: 1631

Confirmation No.: 7166

TRANSMITTAL

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find the following:

1. Information Disclosure Statement under 37 CFR § 1.97 (c): 2 pages
2. PTO Form SB/08A: 1 page
3. PTO Form SB/08B: 1 page
4. References (16)
5. Check in the amount of \$180.00 for Information Disclosure Statement pursuant to 37 C.F.R. § 1.17(p).
6. Return postcard

Please direct all communications regarding this application to the undersigned at the address given below.


Respectfully submitted,

Date: December 4, 2003

By: Sean Brennan

Sean M. Brennan
Registration No. 39,917

Sangamo BioSciences, Inc.
501 Canal Blvd., Suite A100
Richmond, California 94804
Telephone: (510) 970-6000 ext. 252
Facsimile: (510) 236-8951



CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EL 937 422 854 US

Date of Deposit: December 4, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

April Reeves
April Reeves

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

C. Case, *et al.*

Application No.: 09/942,087

Filed: August 28, 2001

For: MODULATION OF ENDOGENOUS
GENE EXPRESSION IN CELLS

Examiner: John S. Brusca

Group Art Unit: 1631

Confirmation No.: 7166

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The information transmitted herewith may be material to the examination of the above-identified application. Copies of the information and completed forms SB/08A and SB/08B are provided herewith. The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement is filed before receipt of either a Final Office Action or a Notice of Allowance, and is accompanied by a fee of \$180.00 pursuant to 37 C.F.R. § 1.17(p).

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or

12/10/2003 HGBREM1 00000038 09942087

01 FC:1806

180.00 OP

enabling; or (iv) the information listed above constitutes prior art to the subject application.


Respectfully submitted,

Date: December 4, 2003

By: Sean Brennan

Sean M. Brennan
Registration No. 39,917

Sangamo BioSciences, Inc.
501 Canal Blvd., Suite A100
Richmond, California 94804
Telephone: (510) 970-6000 ext. 252
Facsimile: (510) 236-8951



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/942,087
		Filing Date	August 28, 2001
		First Named Inventor	C. Case
		Art Unit	1631
		Examiner Name	John S. Brusca
Sheet 2	of 2	Attorney Docket Number	S2-US5

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	F1	ALTINCICEK et al. "Interaction of the corepressor alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal . . ." J. Biol. Chem. 275:7662-7667 (2000)	
	F2	COOK et al. "Three conserved transcriptional repressor domains are a defining feature of the TIEG subfamily. . ." J. Biol. Chem. 274:29500-29504 (1999)	
	F3	CRAWFORD et al. "Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR . . ." Mol. Cell. Biol. 18:2949-2956 (1998)	
	F4	ITO et al. "DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain . . ." Mol. Cell. Biol. 17:1476-1483 (1997)	
	F5	LAI et al. "RBP1 recruits the mSIN3-histone deacetylase complex to the pocket of . . ." Mol. Cell. Biol. 21:2918-2932 (2001)	
	F6	LaPIERRE et al. "Identification of a novel transcriptional repressor encoded by human cytomegalovirus" J. Virology 75:6062-6069 (2001)	
	F7	MAXON et al. "Ash1p is a site-specific DNA-binding protein that actively represses transcription" Proc. Natl. Acad. Sci. USA 98:1495-1500 (2001)	
	F8	SABBATTINI et al. "Binding of Ikaros to the lambda5 promoter silences transcription . . ." EMBO Journal 20:2812-2822 (2001)	
	F9	ZAZOPOULOS et al. "DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis" Nature 390:311-315 (1997)	
	G1	ZHANG et al. "A conserved alpha-helical motif mediates the interaction of Sp1-like transcriptional repressors . . ." Mol. Cell. Biol. 21:5041-5049 (2001)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.